Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis

Barbara A. Fivush; Glenn H. Bock; Philip C. Guzzetta; Jose R. Salcedo; Edward J. Ruley

doi:10.1016/S0272-6386(85)80007-X

Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis

Barbara A. Fivush, Glenn H. Bock, Philip C. Guzzetta, Jose R. Salcedo, Edward J. Ruley

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.

Original language	English (US)
Pages (from-to)	120-123
Number of pages	4
Journal	American Journal of Kidney Diseases
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/S0272-6386(85)80007-X
State	Published - 1985
Externally published	Yes

Keywords

Hemodialysis
PTFE grafts
vancomycin

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/S0272-6386(85)80007-X

Cite this

@article{06e2d429b2d445f387e0f94dc9ba7c05,

title = "Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis",

abstract = "Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.",

keywords = "Hemodialysis, PTFE grafts, vancomycin",

author = "Fivush, {Barbara A.} and Bock, {Glenn H.} and Guzzetta, {Philip C.} and Salcedo, {Jose R.} and Ruley, {Edward J.}",

year = "1985",

doi = "10.1016/S0272-6386(85)80007-X",

language = "English (US)",

volume = "5",

pages = "120--123",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis

AU - Fivush, Barbara A.

AU - Bock, Glenn H.

AU - Guzzetta, Philip C.

AU - Salcedo, Jose R.

AU - Ruley, Edward J.

PY - 1985

Y1 - 1985

N2 - Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.

AB - Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P < .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.

KW - Hemodialysis

KW - PTFE grafts

KW - vancomycin

UR - http://www.scopus.com/inward/record.url?scp=0021924952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021924952&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(85)80007-X

DO - 10.1016/S0272-6386(85)80007-X

M3 - Article

C2 - 3970016

AN - SCOPUS:0021924952

SN - 0272-6386

VL - 5

SP - 120

EP - 123

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 2

ER -

Vancomycin Prevents Polytetrafluoroethylene Graft Infections in Pediatric Patients Receiving Chronic Hemodialysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this